Boeing's CEO Kelly Ortberg faces senators' questions about its recovery from a series of manufacturing and safety crises.

The debate over how Norway's wealth fund should respond to the security landscape comes at a time of higher defense spending and soaring industry profits.

Europe's pharmaceutical sector is bracing for the potential impact of U.S. tariffs as hopes of an industry-wide exemption by President Donald Trump fade.

With its more balanced trading relationship with the U.S., the U.K. is hoping it might escape the full brunt of Trump's import duties.

Chinese military extended into second day a joint exercise involving its army, navy and rocket forces near the coast of Taiwan.

Eli Lilly is suing Strive Pharmacy and Empower Pharmacy for compounding tirzepatide, the active ingredient in Zepbound and Mounjaro.

GM reported a 16.7% jump in U.S. sales compared to the first quarter of 2024, led my incremental gains in sales of new EVs and notable gains in full-size SUVs.

Hims & Hers is adding Zepbound, Mounjaro, and the generic injection liraglutide to its platform.

CNBC's Jim Cramer sees five issues with President Donald Trump's potential 20% blanket tariffs, including their effect on inflation and domestic manufacturing.

JPMorgan Chase and Citigroup are serving as lead underwriters in Circle's IPO, according to the prospectus.

As the U.S. president weighs increasing tariffs on imports, economists find that prices across many categories could rise as a result.

President Donald Trump has announced tariffs for a variety of political and economic reasons. Here's how Americans can prepare for potential price swings.

A drop in consumer confidence and a decline in travel spending is weighing on travel stocks.

President Trump's 'Liberation Day' tariffs on countries around the world will hit food and consumer businesses particularly hard, say CEOs in the sector.

Newsmax shares soared for a second day after their public debut, as the conservative news channel gains traction during President Donald Trump's second term.

White House trade adviser Peter Navarro said tariffs would raise about $600 billion to $700 billion a year. Economists say that's nearly impossible.

President Donald Trump's secondary tariffs are "unprecedented and legally questionable," according to the consulting firm Rapidan Energy.

CoreWeave shares rallied nearly 42% on Tuesday and bounced back from a lackluster second trading day on the public markets.

President Donald Trump is set Wednesday to begin the biggest gamble of his nascent second term.

The long-term trends that should lift cybersecurity stocks remain intact despite a volatile market in 2025.

Meta Vice President of AI Research Joelle Pineau will leave the social media company on May 30.

By the fall, all federal departments and agencies will phase out the use of paper checks and switch to electronic payments, according to the White House.

Trump's reciprocal tariffs follow other import duties he has already announced, including tariffs on goods from Canada and Mexico and industry-specific tariffs.

Luigi Mangione is accused of stalking UnitedHealthcare CEO Brian Thompson and killing him outside a New York hotel in December.

AstraZeneca's new cholesterol pill is showing promise, while the FTC urged a potential buyer of 23andMe to protect user data.

The Apex strategy from Cliff Asness' firm, which combines stocks, macro and arbitrage trades with $3 billion in assets under management, gained 9% in Q1.

"HHS cannot be led by an anti-vax, conspiracy theorist with inadequate training," said analysts at investment firm Cantor Fitzgerald.

The Washington Post report comes a day before April 2, when President Donald Trump is set to announce his larger plans for global trade